MedPageToday -- Two small-molecule kinase inhibitors appear to be effective at extending progression-free survival in pancreatic neuroendocrine tumors, researchers say. In patients with advanced disease enrolled in phase III trials, both everolimus, an mTOR inhibitor, and sunitinib, a tyrosine kinase inhibitor, each halted disease progression significantly longer than placebo, according to two studies in the Feb. 10 issue of the New England Journal of Medicine.
